Vislube

Sodium Hyaluronate

Method of action: Analgesic, Anti-Inflammatory, Corrective Metabolism Of Bone And Cartilaginous Tissue, Other Drugs For Disorders Of The Musculo-Skeletal System

Treatment option: Glaucoma, Cataract, Corneal Transplant, Surgery, Cataract Extraction

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vislube

What is Vislube? An Overview

Property	Description
Active Ingredient	Sodium Hyaluronate (0.18%)
Form	Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class	Ocular Lubricant / Tear Substitute
Common Use	Relief from Ocular Dryness and discomfort
Origin	Natural Polymer Derivative

What Type of Ocular Preparation is Vislube?

Vislube is a sterile ophthalmic solution classified as a medical device, not a prescription drug. It functions as a tear substitute and ocular lubricant, belonging to the pharmacological class of tear substitutes. The product is manufactured by TRB Chemedica, distinguishing it as a specific commercial brand in the market. Its general purpose is to provide effective relief from the common, irritating symptoms of ocular dryness, such as burning and the foreign body sensation. Clinical data confirm that tear substitutes containing hyaluronic acid are effective for surface wetting and lubrication in dry eye disease. This provides patients with assurance that the product is a medically recognized option for stabilizing the protective moisture layer on the eye.

Composition: Sodium Hyaluronate and Unique Formulation

The primary active ingredient in Vislube is Sodium Hyaluronate at a concentration of 0.18%. This component is the salt form of Hyaluronic acid (HA), a highly biocompatible natural polymer. A crucial differentiating factor is the formulation as a preservative-free aqueous solution, often administered in sterile monodose units for topical ocular application. This preservative-free design makes it particularly suitable for individuals with sensitive eyes. Furthermore, the solution is characterized by its hypotonic nature, which is clinically recognized for actively helping to counteract the hyperosmolarity of a stressed tear film. The inclusion of essential ions like potassium chloride and calcium chloride ensures the solution mimics the basic electrolyte profile of native tears, promoting better cellular tolerance.

The General Purpose of This Viscoelastic Solution

The therapeutic benefit of Vislube is rooted in the unique physical properties of its Sodium Hyaluronate content. As a highly viscoelastic solution, it adheres robustly to the ocular surface, forming a protective, lubricating layer that minimizes friction during blinking. This superior coating, combined with HA’s exceptional water retention capacity, ensures prolonged hydration and tear film stabilization. This action effectively counteracts the stress of tear hyperosmolarity, offering sustained comfort for individuals experiencing persistent discomfort from ocular dryness or strain.

What side effects are possible with Vislube?

Possible Side Effects and Safety Information

The safety profile for Vislube, an ophthalmic solution, is based primarily on local tolerance, as documented in regulatory sources for this class of non-systemic products. Adverse reactions are generally localized to the eye and are transient.

Official Adverse Reaction Classification

The most common adverse reactions reported are those associated with Eye Disorders and are typically mild, short-lived, and occur locally upon instillation. These effects are classified according to regulatory frequency standards.

Classification	System-Organ Class	Example Adverse Reaction (as per regulatory labels)
Common	Eye Disorders	Ocular irritation, foreign body sensation, stinging, or burning.
Time-Related Pattern	Eye Disorders	Transient blurred vision immediately following application.

Serious adverse reactions are rare. The regulatory safety profile lists the possibility of a Hypersensitivity reaction (allergic response), which is associated with the Immune System Disorders category and is typically classified as occurring on very rare occasions or with a frequency of not known.

Regulatory Safety Restrictions

The most critical safety constraint documented in official product information is the absolute contraindication for individuals with a known hypersensitivity to any component of the formulation, including Sodium Hyaluronate.

In terms of exposure-related safety, the product is noted as being suitable for use with contact lenses. Furthermore, a high-level safety note advises that if other eye products are needed, an interval of at least 15 minutes should be allowed between applications to prevent potential modification of effects. Because the product is preservative-free, a safety constraint dictates that opened single-dose units must not be stored or reused to avoid contamination risks.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation classifies the risk of systemic overdosage with Vislube (Sodium Hyaluronate 0.18% Ophthalmic Solution) as negligible. This assessment is based on the product's classification as an ocular lubricant and its route of administration. Since Vislube is applied topically to the eye and the active ingredient is minimally absorbed systemically, life-threatening or toxic outcomes are not anticipated by regulatory authorities.

Overdose Scope

Domain	Official Regulatory Statement
Documented Manifestations	No problems of overdosage are expected. The only documented presentation of applying excess product is the flow of excess fluid from the eye.
Physiological Systems Affected	None. Systemic toxic effects are not observed due to minimal ocular absorption.
Emergency-Response	Immediate medical attention is not mandated for over-instillation. Management is limited to wiping off the excess liquid.

Overdose Classifications (High-Level)

Classification	Official Regulatory Statement
Severity Classification	Overdosage is officially classified as non-toxic with no anticipated severe outcomes.

Official Overdose Statements

Regulatory documents consistently state that no problems of overdosage are expected following topical ocular administration.
There is no requirement explicitly stated by regulatory authorities to seek immediate medical attention for over-instillation alone.

Connection to the overall overdose profile: The regulatory documents define the overdose profile as one with negligible risk of systemic toxicity. Due to the product's physical properties and low absorption, over-instillation is self-limiting and non-toxic. This assessment eliminates the need for regulator-mandated urgent medical attention or specific antidote administration.

Therapeutic Uses of Vislube

What Vislube Treats: Main Uses and Benefits

Vislube is commonly used across conditions presenting with chronic and recurrent Dry Eye Disease (DED) and related clinical presentations, such as Keratoconjunctivitis Sicca, where additional symptomatic support is needed. The product is applied in addressing symptoms related to physical discomfort, which include burning, scratchiness, grittiness, and the acute feeling of a foreign body in the eye. Topical lubricants are generally applied for symptomatic support of this common condition.

The formulation is relevant for managing symptom clusters that may become intense or disruptive, specifically ocular irritation and friction. It provides support that helps ease the overall symptom load associated with symptoms that interfere with daily functioning. The product is also considered relevant for managing episodic manifestations of dryness and fatigue triggered by specific external factors. This includes use during phases of increased distress due to extended computer screen use, prolonged contact lens wear, or exposure to harsh environmental factors like air conditioning or wind. It offers symptomatic relief and helps patients cope more steadily with temporary phases of heightened discomfort.

Quick Fact: Supportive Role in Ocular Discomfort The product is relevant for easing symptoms related to physical discomfort associated with chronic dryness, frictional irritation, and environmental strain.

Regulatory References

NIH MedlinePlus overview of Dry Eyes

Eligibility and Restrictions for Use

Vislube is an ophthalmic solution whose official regulatory profile defines patient eligibility primarily by ruling out hypersensitivity to its ingredients, with few other restrictions due to its local, non-systemic action.

Eligibility Scope

Classification	Rule from Regulatory Documents
Absolute Contraindication	Known hypersensitivity or allergy to Sodium Hyaluronate or any other component in the formulation.
Allowed Population	General population seeking symptomatic relief; explicitly approved for use by contact lens wearers (both soft and rigid).

Population-Specific Status

Official labeling does not impose restrictions on use based on major systemic conditions or specific life stages:

Age-Related Eligibility: There are no documented minimum age limitations or specific warnings for older adults in the product label.
Pregnancy and Lactation: No specific restrictions or warnings are documented for individuals who are pregnant or breastfeeding.
Systemic Comorbidities: Use is not restricted in patients with conditions such as severe hepatic impairment or renal impairment, consistent with the product's purely topical application.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vislube (a formulation containing sodium hyaluronate) is an ophthalmic solution with a very simple interaction profile, primarily concerning the use of other products in the eye at the same time. The active substance is generally confined to the eye's surface, which limits the potential for systemic drug-drug interactions with oral or injectable medications.

Ophthalmic Products

The only documented interactions relate to other medicinal products or devices applied directly to the eye. It is noted that Vislube may physically alter the effect or the time of contact of another eye drop or product. This is a procedural interaction rather than a chemical or systemic drug interaction.

Interacting Product Category	Interaction Type	Constraint
Any drug or product applied to the eye	Physical interference/Modification of effect	Do not use simultaneously

Spacing Requirement

To prevent the physical interference of the two products, a mandatory time interval must be followed. Individuals using any other type of ophthalmic medication, such as prescription eye drops for glaucoma, antibiotics, or steroid drops, must wait a minimum of 15 minutes between the installation of Vislube and the other eye product. This spacing is intended to allow adequate time for the first product to be absorbed or act on the eye's surface before the second product is introduced.

No clinically significant interactions with systemic medications (taken by mouth or injection) are formally documented in official regulatory labeling for this type of ophthalmic preparation.

Mechanism of Action

Vislube contains sodium hyaluronate and a hypotonic, electrolyte-balanced formulation. Its mechanism of action operates through distinct physicochemical and biophysical domains that influence the ocular surface environment.

Viscoelastic Film Stabilization and Surface Coating

This domain relies on the physicochemical properties of the long-chain sodium hyaluronate polymer. The molecule forms a stable coating over the ocular surface and any contact lens materials. This viscoelastic effect reduces the coefficient of friction during the blink cycle and modulates the evaporation rate of the tear film. This interaction results in the formation of a sustained surface coating across the corneal and conjunctival epithelia, altering the fluid dynamics of the tear layer.

Osmotic Regulation and Cellular Water Modulation

This domain is driven by the hygroscopic nature of sodium hyaluronate and the hypotonic formulation. Sodium hyaluronate exhibits high water-binding capacity, which facilitates the uptake and retention of water at the epithelial surface. Concurrently, the hypotonicity of the solution creates an osmotic gradient that promotes the regulated flow of water across the epithelial membrane. This combined action serves to modulate the osmotic characteristics of the surface fluid layer and influence cellular volume.

Dosage and Administration Information

How to Use Vislube: Official Administration Guidelines

Vislube is an ocular solution, or eye drops, intended for topical administration to the affected eye(s). The official usage instructions govern the specific volume, frequency, and method of application.

Administration and Dosing

Guideline Element	Official Instruction
Route of Administration	Ocular (into the affected eye(s))
Dosing Schedule	Instill one or two drops
Frequency	As needed, up to four times daily

Procedural Steps and Constraints

The usage protocol is designed to ensure the product's integrity and correct application. It is imperative to follow these steps strictly as documented in the regulatory labeling:

Instillation: Instill the prescribed number of drops (one or two) into the affected eye(s).
Aseptic Handling: To prevent contamination, do not touch the tip of the container to the eye, eyelid, or any other surface during application.
Post-Use Handling: Replace the cap immediately after using the product.
Product Integrity Check: Do not use the solution if it appears to change color or becomes cloudy. The drops are intended for external use only.
Maximum Duration: Use is subject to a maximum frequency of four times per day. The product should only be used as long as symptoms persist, with a constraint that if the condition worsens or does not improve within 72 hours, a healthcare provider should be consulted.

This structured usage map dictates the authorized application of the solution, ensuring the user follows the standardized procedures outlined by government health authorities.

Recent Clinical Evidence

Evidence for Use in Ocular Dryness and Disease

Clinical research, primarily consisting of Randomized Controlled Trials (RCTs) and systematic reviews, explores outcomes related to ocular dryness and discomfort in adult populations. These studies examine both patient-reported outcomes (such as burning and grittiness) and objective measurements, including the integrity of the eye’s surface and Tear Film Break-Up Time (TBUT)—a measure of tear film duration.

Studies reported that the solution was observed in trials exploring how symptoms change over time in patients with mild to moderate symptoms. Findings describe patterns related to how patients reported their experience of discomfort and how physical measurements evolved during the study periods.

Comparative Research and Study Limitations

Research also examined the specific hypotonic formulation of this solution in comparative contexts against other types of ocular lubricants. Some trials described findings that indicate patterns related to the hypotonic design. However, data are still emerging from these comparative studies, and findings were mixed in some contexts, reflecting variations in study design.

Most evidence is derived from short-term (a few weeks) and intermediate (up to 3 months) observation intervals. There is limited information for long-term outcomes regarding the solution, meaning long-term effects may not be fully established. Data for specific groups, such as individuals with the most severe Dry Eye Disease, remain insufficient, and sample sizes for sub-groups like post-surgical patients were often modest.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vislube (FAQ)

Q: What is the typical duration of relief a user can expect from one application of Vislube?

The product's main ingredient, sodium hyaluronate, is a viscoelastic substance that forms a protective film over the ocular surface. The film's characteristics are described as promoting sustained comfort and prolonged hydration because it is slowly eliminated from the eye during the natural blink cycle. Official information indicates this action provides long-lasting relief.

Q: What symptoms should prompt a user to suspect an allergic reaction to Vislube?

The official safety profile notes the possibility of a Hypersensitivity reaction, which is a type of allergic response, as a rare adverse reaction. However, regulatory documents do not provide a detailed list of specific allergic symptoms to look for. Hypersensitivity to any component in the formulation is listed as an absolute contraindication for use.

Q: Are there any known long-term safety concerns with the ingredients in Vislube?

Clinical evidence is primarily based on short-term (a few weeks) and intermediate (up to three months) observation intervals. Because of this, official sources state that there is limited information for long-term outcomes regarding the solution's use beyond this timeframe. The product's preservative-free nature is particularly suitable for sensitive eyes and frequent use, consistent with the official formulation description.

Q: Can Vislube be used after having LASIK or other eye surgeries?

Official research evidence has included sub-groups of post-surgical patients, though the data available from these groups were often modest and insufficient for long-term conclusions. The product is generally used to relieve symptoms of ocular surface damage. Consultation with a healthcare provider is appropriate regarding its use following eye surgery.

Q: Is Vislube suitable for treating moderate to severe dry eye symptoms?

Clinical trials primarily focused on patients experiencing mild to moderate symptoms of dry eye. Official sources indicate that data for individuals with the most severe Dry Eye Disease remain insufficient. For individuals with severe eye conditions, seeking guidance from a healthcare professional is recommended.

Q: Can Vislube be refrigerated for a cooling sensation, and is this safe?

Official instructions state that Vislube must be stored at a temperature not exceeding 25°C (room temperature) and must not be frozen. Storage in a refrigerator is permissible, provided the solution does not freeze, as the official storage requirement is to not exceed 25°C.

Q: Is it safe to use Vislube immediately before operating machinery or driving?

Official safety information lists transient blurred vision as a common side effect immediately following application. The official precaution states that due to this potential temporary visual disturbance, operating machinery or driving should be avoided until vision has fully cleared. This precaution is detailed in official labeling.

Q: Why is Vislube sold in single-dose vials instead of a multi-dose bottle?

Vislube is formulated as a preservative-free solution. The single-dose unit is a safety feature that prevents the risk of microbial contamination, which can occur when preservative-free solutions are used repeatedly from a multi-dose bottle. For this reason, official instructions state that any unused solution must be discarded immediately after the first application.

Q: Can Vislube be used in conjunction with eye ointments or gels?

Regulatory documents specify a waiting period of at least 15 minutes between the installation of Vislube and the application of any other drug or product applied to the eye. This constraint is necessary to prevent the physical interference of the two products, allowing adequate time for the first product to be absorbed before the second is introduced.

Q: Does Vislube contain any ingredients to help specifically with eye redness?

The product's components are sodium hyaluronate and an electrolyte-balanced solution, which are intended solely for lubrication and tear film stabilization. The official product overview indicates that Vislube does not contain any active substances such as vasoconstrictors, which are typically found in drops specifically for reducing eye redness.

Q: What is the shelf life of an unopened carton of Vislube vials?

Vislube is noted to have a common shelf life of 3 years from the date of manufacture. This shelf life applies to the unopened carton, provided the product has been stored correctly according to the temperature and light protection requirements.

Q: Has Vislube been clinically tested on patients with Sjögren’s syndrome?

Official indications for this class of ocular lubricant products often include the lubrication of eyes where dry eye symptoms are caused by underlying diseases. Specifically, similar sodium hyaluronate-based products are indicated for relieving symptoms due to conditions such as Sjögren syndrome.

Q: Does the single-use format of Vislube mean it is completely sterile until use?

Yes, Vislube is supplied as a sterile ophthalmic solution in sterile monodose units. The product's sterility is maintained within the unopened unit. To prevent contamination after opening, the official protocol states that any unused solution must be discarded immediately.

Q: Are there any ingredients in Vislube that can cause crusting on contact lenses?

Official product information notes that Vislube is suitable for use with contact lenses and is formulated so that it does not leave any deposits or crusts on the lens material.

Q: Is it safe to share a box of Vislube single-dose vials with another household member?

The single-dose vial is intended for immediate, single use only by the individual user. The official instructions emphasize aseptic handling to prevent contamination. Because of these constraints, the product is indicated for individual use only, and sharing is not advised.

How should Vislube be stored and disposed of?

How to Store and Dispose of Vislube?

Vislube, a sterile ophthalmic solution, must be handled according to specific rules to maintain its sterility and stability.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25°C (room temperature).
Prohibition	The product must not be frozen and should be protected from light by keeping it in the original carton.
Child Safety	Like all medicines, keep Vislube out of the sight and reach of children.

Handling and Disposal

The preservative-free single-dose container is for immediate, single use only. Any unused solution must be discarded immediately after the first application, and the container must not be reused. Dispose of unused or expired Vislube in accordance with local requirements and not via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Germany

Thailand

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z